After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Get the (EPIX) Report Here
Trade with Jim Cramer 14 Days FREE
Struggling Mass. biotech firm Epix Pharmaceuticals explores strategic options, including sale
Epix Pharmaceuticals may file for bankruptcy protection; offers cash and stock for debt
It may be best to wait for data from two clinical studies on Alzheimer's drug PRX-03140 before making any predictions about its prospects.
EPIX plunges after ending development of its depression drug.
Stereotaxis' delayed catheter gets FDA approval.
A wild day leaves major averages slightly higher. James Bianco opines on the credit crunch, and Dan Fitzpatrick on the search for Santa.
Adobe rises on earnings; iRobot shares salute Army contract.
Epix Pharma climbs on study data.
OSI Pharma gains on an analyst upgrade.
HemoSense climbs on merger news.
CryoCor soars on a positive recommendation from an FDA panel.
Yahoo! climbs on news of a CEO change.
The British drug giant's deal with Genmab is its third in 11 days.
Valera takes off.
The companies pledge to develop drugs based on G-protein receptors.
Epix Pharmaceuticals sinks 15.6% on disappointing study results of its experimental anxiety drug.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.